Advances in Dendritic Cell-Based Immunotherapy of Cancer
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".
Deadline for manuscript submissions: 31 December 2025 | Viewed by 132
Special Issue Editors
2. Laboratory of Cell Engineering, Celica Biomedical, Ljubljana, Slovenia
Interests: cell biology; cell physiology; neurobiology; membrane properties; cell metabolism; therapeutic biotechnology; preparation of cell-based therapies for the treatment of solid cancers; clinical trials
2. Laboratory of Cell Engineering, Celica Biomedical, Ljubljana, Slovenia
Interests: cellular immunology; immunomodulation; cell and tissue engineering; advanced cell immunotherapies; regenerative medicine
Special Issue Information
Dear Colleagues,
Dendritic cells (DCs) have been extensively studied since their description in 1973 by Ralph Steinman and Zanvil Cohn. Since then, DCs have been recognized as playing a key role in mediating the innate and inducing the acquired (specific) immune responses. They are the most potent antigen-presenting cells (APCs), capable of activating both naive and memory immune responses. DCs have a superior capacity to acquire and process antigens for presentation to T cells and express high levels of costimulatory or coinhibitory molecules that determine immune activation by initiating a cascade of cellular immune responses, or anergy.
Over the past two decades, DCs have been used in clinical settings against various types of cancer. The use of dendritic cells (DCs) for tumor immunotherapy empowers patients’ own immune effector cells to eliminate tumor cells; however, there are still many important questions to be answered in order to achieve better clinical outcomes with this therapeutic approach, such as the in vitro generation of potent immunostimulatory DCs, their dosage and routes of administration, their body distribution post-application, their frequency and continuity of applications, the inhibition of tumor immunosuppressive regulatory mechanisms, and combinatorial DC-based immunotherapy, e.g., with immune checkpoint inhibitors and certain other types of anticancer drugs.
The aim of this Special Issue is to provide insights into some of these important aspects related to the use of DCs in cancer immunotherapy and suggest new approaches that may be key for achieving effective and durable anticancer immune responses with better clinical outcomes in patients.
Dr. Helena Haque Chowdhury
Dr. Matjaz Jeras
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- DC-based immunotherapy of cancer
- immunostimulatory dendritic cell (DC) generation
- dosage and routes of DC administration
- body distribution of DCs post-application
- frequency and duration of DC applications
- tumour immunosuppressive mechanisms’ modulation
- combinatorial DC-based anticancer immunotherapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
